MERZ-AESTHETICS

3.6.2022 09:02:06 CEST | Business Wire | Press release

Merz Aesthetics presents data at the IMCAS World Congress 2022

Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 2022 International Master Course on Aging Science (IMCAS) World Congress, with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diversifying society and a younger patient base. IMCAS, held from Friday, June 3 to Sunday, June 5, 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Paris and/or virtually. Merz Aesthetics is a diamond sponsor of the global industry congress.

“This year’s IMCAS Congress is an opportunity to reunite with our partners and leading experts in dermatology, plastic surgery and aging science to bridge our respective fields and drive innovation in aesthetic medicine forward,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We exist to fuel confidence by helping people look better, feel better and live better, and we’re proud to present research across our portfolio that reinforces the need for diverse and expansive experiences for every patient.”

Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs. As patients are starting their aesthetic journey earlier in their lives, Merz Aesthetics stands for a long term and responsible view on how patients are treated.

Merz Aesthetics is organizing a program led by esteemed medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the course of the meeting.

Merz Aesthetics Symposium #Beautification – Embracing #Uniqueness, Advanced aesthetic strategies for the needs of diverse generations – Dr. Gabriela Casabona, Dr. Daria Voropai, Dr. Raj Aquilla, Sunday, June 5, 2022 | 10:30 – 12:30h CEST
Merz Aesthetics support of IMCAS Cadaver Workshop with anatomist Prof. Dr. Thilo Schenck and Live Injector: Dr. Fouad Belfkira - Friday, June 3, 2022 10:30 – 11:00h CEST
Product Analysis Session “Emerging Toxins”, Andy Curry, Assoc. Med. Director, Merz Aesthetics - Friday, June 3, 2022, 8:30 - 12:00 h CEST
Innovation Tank, Dr. Samantha Kerr, CSO, Merz Aesthetics, Friday, June 3, 2022, 8:30 -12:00h CEST
IMCAS Economic Tribune Round Table, Bob Rhatigan, CEO Merz Aesthetics, Saturday, June 4, 2022, 16:00 – 18:00h CEST

E-Poster Presentations

Virtual posters will be available for viewing on site for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.

Botulinum Toxin

Study Design of LONG RUN: A longitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants. Presenting author: Andy Curry , Merz Aesthetics – USA, Terrence Keaney, MD – USA, Karyn Siemasko, PhD -USA

IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Presenting author: Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.

Belotero^® and Radiesse^®

A Hybrid Filler: Combining Calcium Hydroxylapatite and Hyaluronic Acid Fillers for Aesthetic Indications, Presenting author: Jonathan Kadouch , MD, PhD – Netherlands, Nabil Fakih-Gomez, MD-Lebanon.

Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Presenting author: Yana Yutskovskaya , MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.

Technical evaluation and comparison of calcium hydroxylapatite (CaHA) containing dermal fillers, Sarah Backfisch, Radia El-Banna, Presenting author: Cleiton Kunzler , Roland Stragies, and Nadine Hagedorn, Merz Aesthetics GmbH – Germany.

Increased hyaluronic acid concentration enhances the local tissue lifting capacity in an ex vivo human skin model, Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.

Animal study indicates importance of distance between microspheres for neocollagenesis, Bartosch Nowag, Nils Warfving, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005010/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release

Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g

Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press release

Partnership combines Energy Vault's FEOC-compliant BESS, grid-forming PCS, and AI infrastructure control software with partner’s turnkey power generation, Caterpillar gensets and EPC capabilitiesReference architecture delivers firm grid-independent power, essential grid stabilization and load balancing to deliver modular, scalable, gigawatt-scale AI campuses with "always-on" availabilitySecond strategic framework agreement together advances Energy Vault's AI infrastructure strategy and establishes a repeatable “speed-to-power” deployment platformInitial 1.25 GW is backed by a hyperscaler customer contract for deployment in TexasEnergy Vault expects a revenue impact of ~$500 - $600 million in 2H 2026 and 2027, which will be discussed during the upcoming earnings call on August 11, 2026 Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault

SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press release

IRIS² expands SES's differentiated MEO architecture while supporting Europe's secure, sovereign multi-orbit connectivity ambitions SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously commun

Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release

2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom